Evidence map›Paper›PMID 41357757›Full record

ArticleFrontiers in veterinary science2025

Cathepsin K inhibition by VBX1000 alleviates canine periodontitis.

Jerzy Gawor, Daria Ziemann Gawor, Isabelle Druet, Julien Salindre, Alicja Gajosz, Paweł Kowalczyk, Noémie Dam, Dominique Tierny, Matthieu Dubruque, Rémy Hanf

Abstract read
In one paragraph

Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jerzy GaworKlinika Weterynaryjna Arka, Krakow, Poland.
Daria Ziemann GaworKlinika Weterynaryjna Arka, Krakow, Poland.
Isabelle DruetAlliance, Bordeaux, France.
Julien SalindreClinique Vétérinaire VPLUS, Mirambeau, France.
Alicja GajoszVeterinary Clinic KoniczynaVET, Warsaw, Poland.
Paweł KowalczykBraci Mniejszych Veterinary Clinic, Konstantynow Lodzki, Poland.
Noémie DamVetbiolix, Loos, France.
Dominique TiernyOCRvet dba Clinaxel, Lille, France.
Matthieu DubruqueVetbiolix, Loos, France.
Rémy HanfVetbiolix, Loos, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The efficacy and safety of a novel cathepsin K inhibitor, VBX1000, were evaluated in client-owned dogs suffering from periodontal disease. Methods: This open-label study recruited twenty dogs ( Results: Throughout the treatment period, VBX1000 was well tolerated. At Day60, plasma CTX1 was significantly and similarly reduced compared with baseline ( Conclusion: The findings support the inhibition of cathepsin K by VBX1000 as a new therapeutic approach for mild-to-moderate periodontal disease in dogs. A randomized, double blinded placebo-controlled trial in dogs should confirm the potential of VBX1000 in this indication.

Indexed as

canine periodontitiscathepsin Kefficacyopen-label studysafetyVBX-1000

Identifiers

PMID41357757
PMCPMC12679828

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.